Noticias y notas de prensa
Manténgase al día con las noticias y los eventos de la Asociación.
Acceso Rápido
Notas de Prensa
Comunicados PPTA
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jul 21, 2005
Statement on Update on Safety of Albumin
The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.
All
PPTA statements
Jul 21, 2005
Statement on Update on Safety of Albumin
The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.
All
PPTA statements
Oct 21, 2004
PPTA Statement on Review of Donor Weight Loss Monitoring
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Oct 21, 2004
PPTA Statement on Review of Donor Weight Loss Monitoring
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Jul 22, 2004
PPTA Statement on Review of Donor Blood Pressure Requirements
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Jul 22, 2004
PPTA Statement on Review of Donor Blood Pressure Requirements
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.
All
PPTA statements
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.
All
PPTA statements
No results found